

Filtr: Česká republika, minimální četnost skupin n = 5

## Cyklus EHK: E23/22 - Endokrinologie 2

Stop termín: 26.07.2022

|   |   |                                       |
|---|---|---------------------------------------|
| RoM = robustní průměr                           | AV = vztažná hodnota  | Dmax = přijatelný rozdíl v procentech |
| SD = směrodatná odchylka                        | CRV = certifikovaná referenční hodnota                        | LL = dolní mez                        |
| CV = variační koeficient                        | RV = referenční hodnota                                       | UL = horní mez                        |
| Ntot = celkový počet účastníků                  | CVE = konsenzus expertů                                       | Neva = počet hodnocených účastníků    |
| Nout = počet výsledků vyloučených před výpočtem | CVP = konsenzus všech účastníků                               | Nsuc = počet úspěšných účastníků      |
|   | CVPG = konsenzus skupin účastníků                             | Srel = relativní úspěšnost            |
|   | U <sub>AV</sub> = rozšířená nejistota vztažné hodnoty (k = 2) |                                       |

| zkouška  | [jednotka] |      |      |        |                  |                  | Srovnatelnost |  |                  |     |      |                  |                  |                  |
|--|------------|------|------|--------|------------------|------------------|---------------|--|------------------|-----|------|------------------|------------------|------------------|
|  |            | RoM  | SD   | CV [%] | N <sub>tot</sub> | N <sub>out</sub> | AV            | U <sub>AV</sub>  | D <sub>max</sub> | LL  | UL   | N <sub>eva</sub> | N <sub>suc</sub> | S <sub>rel</sub> |
| <b>(393) C-peptid</b>                                      |            |      |      |        | 24               |                  |               |  |                  |     |      | 18               | 18               | 100%             |
| Vzorky a skupiny   | [pmol/L]   |      |      |        |                  |                  |               |  |                  |     |      |                  |                  |                  |
| <b>Vzorek A</b>  |            | 384  | 83   | 22     | 24               |                  |               |  |                  |     |      | 18               | 18               | 100%             |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(1) Abbott           |            | 381  | 32   | 8,3    | 8                | 0                | CVPG          | 376  | 18               | 20% | 300  | 452              | 8                |                  |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(60) Roche           |            | 448  | 26   | 5,9    | 8                | 0                | CVPG          | 457  | 21               | 20% | 365  | 549              | 8                |                  |
| Ostatní  |            |      |      |        | 8                | 0                |               |  |                  |     |      |                  | 2                |                  |
|  |            |      |      |        |                  |                  |               | 2x 4/12, 1x 4/29, 2x 4/162, 1x 4/164, 2x 4/179                           |                  |     |      |                  |                  |                  |
| <b>Vzorek B</b>  |            | 159  | 35   | 22     | 24               |                  |               |  |                  |     |      | 18               | 18               | 100%             |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(1) Abbott           |            | 142  | 14   | 10     | 8                | 0                | CVPG          | 140  | 8,0              | 20% | 112  | 168              | 8                |                  |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(60) Roche           |            | 184  | 11   | 5,9    | 8                | 0                | CVPG          | 189  | 11               | 20% | 151  | 227              | 8                |                  |
| Ostatní  |            |      |      |        | 8                | 1                |               |  |                  |     |      |                  | 2                |                  |
|  |            |      |      |        |                  |                  |               | 2x 4/12, 1x 4/29, 2x 4/162, 1x 4/164, 2x 4/179                           |                  |     |      |                  |                  |                  |
| <b>(193) Feritin</b>                                       |            |      |      |        | 34               |                  |               |  |                  |     |      | 32               | 31               | 97%              |
| Vzorky a skupiny   | [µg/L]     |      |      |        |                  |                  |               |  |                  |     |      |                  |                  |                  |
| <b>Vzorek A</b>  |            | 353  | 64   | 18     | 34               |                  |               |  |                  |     |      | 32               | 32               | 100%             |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(1) Abbott           |            | 408  | 24   | 6,0    | 9                | 0                | CVPG          | 395  | 9,0              | 24% | 300  | 490              | 9                |                  |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(60) Roche           |            | 384  | 33   | 8,6    | 10               | 0                | CVPG          | 367  | 4,3              | 24% | 278  | 456              | 10               |                  |
| Ostatní  |            |      |      |        | 15               | 0                |               |  |                  |     |      |                  | 13               |                  |
|  |            |      |      |        |                  |                  |               | 2x 4/12, 2x 4/29, 1x 4/149, 2x 4/162, 1x 4/179, 2x 6/1, 3x 6/58, 2x 6/60 |                  |     |      |                  |                  |                  |
| <b>Vzorek B</b>  |            | 40,3 | 9,3  | 23     | 34               |                  |               |  |                  |     |      | 32               | 31               | 97%              |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(1) Abbott           |            | 37,2 | 4,7  | 13     | 9                | 0                | CVPG          | 36,2   | 1,3 ±16,8        |     | 19,4 | 53               | 9                |                  |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(60) Roche           |            | 48,0 | 6,0  | 12     | 10               | 0                | CVPG          | 44,4   | 0,76 ±16,8       |     | 27,6 | 61,2             | 10               |                  |
| Ostatní  |            |      |      |        | 15               | 0                |               |  |                  |     |      |                  | 13               |                  |
|  |            |      |      |        |                  |                  |               | 2x 4/12, 2x 4/29, 1x 4/149, 2x 4/162, 1x 4/179, 2x 6/1, 3x 6/58, 2x 6/60 |                  |     |      |                  |                  |                  |
| <b>(321) FSH</b>   |            |      |      |        | 26               |                  |               |  |                  |     |      | 26               | 24               | 92%              |
| Vzorky a skupiny   | [U/L]      |      |      |        |                  |                  |               |  |                  |     |      |                  |                  |                  |
| <b>Vzorek A</b>  |            | 27,8 | 2,0  | 7,3    | 26               |                  |               |  |                  |     |      | 26               | 25               | 96%              |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(1) Abbott           |            | 27,6 | 0,72 | 2,6    | 8                | 0                | CVPG          | 27   | 0,30             | 15% | 22,9 | 31,1             | 8                |                  |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(12) Beckman Coulter |            | 27,2 | 1,6  | 5,7    | 6                | 0                | CVPG          | 26,4   | 0,57             | 15% | 22,4 | 30,4             | 6                |                  |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(60) Roche           |            | 26,7 | 2,0  | 7,4    | 7                | 0                | CVPG          | 27   | 0,16             | 15% | 22,9 | 31,1             | 7                |                  |
| Ostatní  |            |      |      |        | 5                | 0                |               |  |                  |     |      |                  | 5                |                  |
|  |            |      |      |        |                  |                  |               | 2x 4/162, 3x 4/179   |                  |     |      |                  |                  |                  |
| <b>Vzorek B</b>  |            | 15,0 | 1,1  | 7,4    | 26               |                  |               |  |                  |     |      | 26               | 24               | 92%              |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(1) Abbott           |            | 14,6 | 0,96 | 6,6    | 8                | 0                | CVPG          | 14,4   | 0,16             | 15% | 12,2 | 16,6             | 8                |                  |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(12) Beckman Coulter |            | 16,0 | 1,5  | 9,3    | 6                | 0                | CVPG          | 16,5   | 0,44             | 15% | 14   | 19               | 6                |                  |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(60) Roche           |            | 14,6 | 0,94 | 6,5    | 7                | 0                | CVPG          | 14,9   | 0,080            | 15% | 12,6 | 17,2             | 7                |                  |
| Ostatní  |            |      |      |        | 5                | 0                |               |  |                  |     |      |                  | 5                |                  |
|  |            |      |      |        |                  |                  |               | 2x 4/162, 3x 4/179   |                  |     |      |                  |                  |                  |
| <b>(328) hGH</b>   |            |      |      |        | 6                |                  |               |  |                  |     |      | 5                | 5                | 100%             |
| Vzorky a skupiny   | [mU/L]     |      |      |        |                  |                  |               |  |                  |     |      |                  |                  |                  |
| <b>Vzorek A</b>  |            | 26,5 | 1,6  | 6,2    | 6                |                  |               |  |                  |     |      | 5                | 5                | 100%             |
| Ostatní  |            |      |      |        | 6                | 0                |               |  |                  |     |      |                  | 5                |                  |
|  |            |      |      |        |                  |                  |               | 1x 1/36, 4x 4/29, 1x 4/60  |                  |     |      |                  |                  |                  |
| <b>Vzorek B</b>  |            | 3,13 | 0,43 | 14     | 6                |                  |               |  |                  |     |      | 5                | 5                | 100%             |
| Ostatní  |            |      |      |        | 6                | 0                |               |  |                  |     |      |                  | 5                |                  |
|  |            |      |      |        |                  |                  |               | 1x 1/36, 4x 4/29, 1x 4/60  |                  |     |      |                  |                  |                  |
| <b>(329) IGF-1</b>   |            |      |      |        | 8                |                  |               |  |                  |     |      | 8                | 8                | 100%             |
| Vzorky a skupiny   | [µg/L]     |      |      |        |                  |                  |               |  |                  |     |      |                  |                  |                  |
| <b>Vzorek A</b>  |            | 286  | 87   | 30     | 8                |                  |               |  |                  |     |      | 8                | 8                | 100%             |
| Ostatní  |            |      |      |        | 8                | 0                |               |  |                  |     |      |                  | 8                |                  |
|  |            |      |      |        |                  |                  |               | 2x 4/29, 3x 4/60, 3x 4/164   |                  |     |      |                  |                  |                  |
| <b>Vzorek B</b>  |            | 116  | 40   | 35     | 8                |                  |               |  |                  |     |      | 8                | 8                | 100%             |
| Ostatní  |            |      |      |        | 8                | 0                |               |  |                  |     |      |                  | 8                |                  |
|  |            |      |      |        |                  |                  |               | 2x 4/29, 3x 4/60, 3x 4/164   |                  |     |      |                  |                  |                  |
| <b>(392) IGF-BP3</b>                                       |            |      |      |        | 3                |                  |               |  |                  |     |      | 3                | 3                | 100%             |
| Vzorky a skupiny   | [µg/L]     |      |      |        |                  |                  |               |  |                  |     |      |                  |                  |                  |
| <b>Vzorek A</b>  |            | 3710 | 320  | 8,7    | 3                |                  |               |  |                  |     |      | 3                | 3                | 100%             |
| Ostatní  |            |      |      |        | 3                | 0                |               |  |                  |     |      |                  | 3                |                  |
|  |            |      |      |        |                  |                  |               | 2x 4/29, 1x 4/60   |                  |     |      |                  |                  |                  |

Filtr: Česká republika, minimální četnost skupin n = 5

## Cyklus EHK: E23/22 - Endokrinologie 2

Stop termín: 26.07.2022

| Zkouška  | [jednotka] |       |        |        |                  |                  | Srovnatelnost |                 |                  |       |       |                  |                  |                  |
|--|------------|-------|--------|--------|------------------|------------------|---------------|-----------------|------------------|-------|-------|------------------|------------------|------------------|
|  |            | RoM   | SD     | CV [%] | N <sub>tot</sub> | N <sub>out</sub> | AV            | U <sub>AV</sub> | D <sub>max</sub> | LL    | UL    | N <sub>eva</sub> | N <sub>suc</sub> | S <sub>rel</sub> |
| <b>Vzorek B</b>  |            | 3680  | 380    | 10     | 3                |                  |               |                 |                  |       |       | 3                | 3                | 100%             |
| Ostatní  |            |       |        |        | 3                | 0                |               |                 |                  |       |       | 3                |                  |                  |
| 2x 4/29, 1x 4/60   |            |       |        |        |                  |                  |               |                 |                  |       |       |                  |                  |                  |
| <b>(325) Inzulín</b>                                       | [mU/L]     |       |        |        | 4                |                  |               |                 |                  |       |       | 4                | 4                | 100%             |
| Vzorky a skupiny   |            |       |        |        |                  |                  |               |                 |                  |       |       |                  |                  |                  |
| <b>Vzorek A</b>  |            | 22,6  | 5,6    | 25     | 4                |                  |               |                 |                  |       |       | 4                | 4                | 100%             |
| Ostatní  |            |       |        |        | 4                | 0                |               |                 |                  |       |       | 4                |                  |                  |
| 2x 4/1, 1x 4/60, 1x 4/179                                  |            |       |        |        |                  |                  |               |                 |                  |       |       |                  |                  |                  |
| <b>Vzorek B</b>  |            | 16,6  | 2,7    | 17     | 4                |                  |               |                 |                  |       |       | 4                | 4                | 100%             |
| Ostatní  |            |       |        |        | 4                | 0                |               |                 |                  |       |       | 4                |                  |                  |
| 2x 4/1, 1x 4/60, 1x 4/179                                  |            |       |        |        |                  |                  |               |                 |                  |       |       |                  |                  |                  |
| <b>(326) Kyselina listová</b>                              | [nmol/L]   |       |        |        | 31               |                  |               |                 |                  |       |       | 31               | 31               | 100%             |
| Vzorky a skupiny   |            |       |        |        |                  |                  |               |                 |                  |       |       |                  |                  |                  |
| <b>Vzorek A</b>  |            | 43,7  | 5,8    | 13     | 31               |                  |               |                 |                  |       |       | 31               | 31               | 100%             |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(1) Abbott           |            | 43,8  | 4,9    | 11     | 10               | 0                | CVPG          | 46              | 1,1              | 27%   | 33,5  | 58,5             | 10               |                  |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(12) Beckman Coulter |            | 51,9  | 0,320  | 0,61   | 5                | 0                | CVPG          | 49,9            | 1,0              | 27%   | 36,4  | 63,4             | 5                |                  |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(60) Roche           |            | 40,7  | 1,6    | 4,0    | 9                | 0                | CVPG          | 40,5            | 0,48             | 27%   | 29,5  | 51,5             | 9                |                  |
| Ostatní  |            |       |        |        | 7                | 0                |               |                 |                  |       |       | 7                |                  |                  |
| 2x 4/29, 1x 4/149, 2x 4/162, 2x 4/179                      |            |       |        |        |                  |                  |               |                 |                  |       |       |                  |                  |                  |
| <b>Vzorek B</b>  |            | 58,3  | 19     | 33     | 31               |                  |               |                 |                  |       |       | 0                |                  |                  |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(1) Abbott           |            | 68,0  | 27     | 40     | 10               | 0                | CVPG          | 62,8            | 6,1              | 27%   | 45,8  | 79,8             | 0                |                  |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(12) Beckman Coulter |            | 54,4  | 1,3    | 2,5    | 5                | 0                | CVPG          | 53,6            | 1,1              | 27%   | 39,1  | 68,1             | 0                |                  |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(60) Roche           |            | 45,4  | 0,0670 | 0,15   | 9                | 0                | CVPG          | 45,4            | 0,0054           | 27%   | 33,1  | 57,7             | 0                |                  |
| Ostatní  |            |       |        |        | 7                | 2                |               |                 |                  |       |       | 0                |                  |                  |
| 2x 4/29, 1x 4/149, 2x 4/162, 2x 4/179                      |            |       |        |        |                  |                  |               |                 |                  |       |       |                  |                  |                  |
| <b>(320) LH</b>  | [U/L]      |       |        |        | 25               |                  |               |                 |                  |       |       | 25               | 24               | 96%              |
| Vzorky a skupiny   |            |       |        |        |                  |                  |               |                 |                  |       |       |                  |                  |                  |
| <b>Vzorek A</b>  |            | 75,3  | 11     | 15     | 25               |                  |               |                 |                  |       |       | 25               | 24               | 96%              |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(1) Abbott           |            | 68,4  | 2,8    | 4,1    | 8                | 0                | CVPG          | 68,9            | 0,89             | 15%   | 58,5  | 79,3             | 8                |                  |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(12) Beckman Coulter |            | 66,6  | 2,8    | 4,2    | 6                | 0                | CVPG          | 64,5            | 1,1              | 15%   | 54,8  | 74,2             | 6                |                  |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(60) Roche           |            | 86,5  | 3,7    | 4,2    | 6                | 0                | CVPG          | 86,2            | 0,56             | 15%   | 73,2  | 99,2             | 6                |                  |
| Ostatní  |            |       |        |        | 5                | 0                |               |                 |                  |       |       | 5                |                  |                  |
| 2x 4/162, 3x 4/179   |            |       |        |        |                  |                  |               |                 |                  |       |       |                  |                  |                  |
| <b>Vzorek B</b>  |            | 7,49  | 1,8    | 24     | 25               |                  |               |                 |                  |       |       | 25               | 25               | 100%             |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(1) Abbott           |            | 5,77  | 0,19   | 3,3    | 8                | 0                | CVPG          | 5,86            | 0,064            | 15%   | 4,98  | 6,74             | 8                |                  |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(12) Beckman Coulter |            | 7,68  | 0,33   | 4,3    | 6                | 0                | CVPG          | 7,39            | 0,13             | 15%   | 6,28  | 8,5              | 6                |                  |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(60) Roche           |            | 9,89  | 0,47   | 4,7    | 6                | 0                | CVPG          | 9,76            | 0,063            | 15%   | 8,29  | 11,3             | 6                |                  |
| Ostatní  |            |       |        |        | 5                | 0                |               |                 |                  |       |       | 5                |                  |                  |
| 2x 4/162, 3x 4/179   |            |       |        |        |                  |                  |               |                 |                  |       |       |                  |                  |                  |
| <b>(407) Parathyrin biointaktní (PTH 1-84)</b>             | [pmol/L]   |       |        |        | 8                |                  |               |                 |                  |       |       | 8                | 8                | 100%             |
| Vzorky a skupiny   |            |       |        |        |                  |                  |               |                 |                  |       |       |                  |                  |                  |
| <b>Vzorek A</b>  |            | 13,5  | 1,9    | 14     | 8                |                  |               |                 |                  |       |       | 8                | 8                | 100%             |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(60) Roche           |            | 14,6  | 0,37   | 2,5    | 6                | 0                | CVPG          | 14,8            | 0,57             | 17%   | 12,2  | 17,4             | 6                |                  |
| Ostatní  |            |       |        |        | 2                | 0                |               |                 |                  |       |       | 2                |                  |                  |
| 2x 4/164   |            |       |        |        |                  |                  |               |                 |                  |       |       |                  |                  |                  |
| <b>Vzorek B</b>  |            | 0,542 | 0,062  | 11     | 8                |                  |               |                 |                  |       |       | 8                | 8                | 100%             |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(60) Roche           |            | 0,582 | 0,0020 | 0,38   | 6                | 0                | CVPG          | 0,581           | 0,0012 ± 0,204   | 0,377 | 0,785 | 6                |                  |                  |
| Ostatní  |            |       |        |        | 2                | 0                |               |                 |                  |       |       | 2                |                  |                  |
| 2x 4/164   |            |       |        |        |                  |                  |               |                 |                  |       |       |                  |                  |                  |
| <b>(405) Parathyrin intaktní (PTH)</b>                     | [pmol/L]   |       |        |        | 16               |                  |               |                 |                  |       |       | 16               | 15               | 94%              |
| Vzorky a skupiny   |            |       |        |        |                  |                  |               |                 |                  |       |       |                  |                  |                  |
| <b>Vzorek A</b>  |            | 22,9  | 3,2    | 14     | 16               |                  |               |                 |                  |       |       | 16               | 16               | 100%             |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(1) Abbott           |            | 25,6  | 1,3    | 5,1    | 6                | 0                | CVPG          | 25,4            | 0,41             | 23%   | 19,5  | 31,3             | 6                |                  |
| Ostatní  |            |       |        |        | 10               | 0                |               |                 |                  |       |       | 10               |                  |                  |
| 3x 4/12, 1x 4/29, 2x 4/60, 2x 4/162, 2x 4/179              |            |       |        |        |                  |                  |               |                 |                  |       |       |                  |                  |                  |
| <b>Vzorek B</b>  |            | 0,390 | 0,14   | 37     | 16               |                  |               |                 |                  |       |       | 16               | 15               | 94%              |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(1) Abbott           |            | 0,290 | 0,045  | 15     | 6                | 0                | CVPG          | 0,352           | 0,025 ± 0,276    | 0,076 | 0,628 | 6                |                  |                  |
| Ostatní  |            |       |        |        | 10               | 0                |               |                 |                  |       |       | 10               |                  |                  |
| 3x 4/12, 1x 4/29, 2x 4/60, 2x 4/162, 2x 4/179              |            |       |        |        |                  |                  |               |                 |                  |       |       |                  |                  |                  |
| <b>(322) Prolaktin</b>                                     | [mU/L]     |       |        |        | 27               |                  |               |                 |                  |       |       | 27               | 27               | 100%             |
| Vzorky a skupiny   |            |       |        |        |                  |                  |               |                 |                  |       |       |                  |                  |                  |
| <b>Vzorek A</b>  |            | 571   | 76     | 13     | 27               |                  |               |                 |                  |       |       | 27               | 27               | 100%             |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(1) Abbott           |            | 612   | 48     | 7,9    | 10               | 0                | CVPG          | 606             | 8,7              | 16%   | 509   | 703              | 10               |                  |

Filtr: Česká republika, minimální četnost skupin n = 5

## Cyklus EHK: E23/22 - Endokrinologie 2

Stop termín: 26.07.2022

| Zkouška  | [jednotka] |      |      |        |                  |                  | Srovnatelnost |                                       |                  |     |      |                  |                  |                  |
|--|------------|------|------|--------|------------------|------------------|---------------|---------------------------------------|------------------|-----|------|------------------|------------------|------------------|
|  |            | RoM  | SD   | CV [%] | N <sub>tot</sub> | N <sub>out</sub> | AV            | U <sub>AV</sub>                       | D <sub>max</sub> | LL  | UL   | N <sub>eva</sub> | N <sub>suc</sub> | S <sub>rel</sub> |
| <b>(322) Prolaktin</b>                                     | [mU/L]     |      |      |        | 27               |                  |               |                                       |                  |     |      | 27               | 27               | 100%             |
| Vzorky a skupiny   |            |      |      |        |                  |                  |               |                                       |                  |     |      |                  |                  |                  |
| <b>Vzorek A</b>  |            | 571  | 76   | 13     | 27               |                  |               |                                       |                  |     |      | 27               | 27               | 100%             |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(12) Beckman Coulter |            | 523  | 51   | 9,7    | 6                | 0                | CVPG          | 514                                   | 8,8              | 16% | 431  | 597              | 6                |                  |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(60) Roche           |            | 625  | 31   | 4,9    | 6                | 0                | CVPG          | 619                                   | 4,0              | 16% | 519  | 719              | 6                |                  |
| Ostatní  |            |      |      |        | 5                | 0                |               |                                       |                  |     |      |                  | 5                |                  |
|  |            |      |      |        |                  |                  |               | 2x 4/162, 3x 4/179                    |                  |     |      |                  |                  |                  |
| <b>Vzorek B</b>  |            | 197  | 30   | 15     | 27               |                  |               |                                       |                  |     |      | 27               | 27               | 100%             |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(1) Abbott           |            | 213  | 16   | 7,6    | 10               | 0                | CVPG          | 213                                   | 3,2              | 16% | 178  | 248              | 10               |                  |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(12) Beckman Coulter |            | 177  | 8,2  | 4,6    | 6                | 0                | CVPG          | 177                                   | 4,1              | 16% | 148  | 206              | 6                |                  |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(60) Roche           |            | 224  | 18   | 8,2    | 6                | 0                | CVPG          | 226                                   | 1,5              | 16% | 189  | 263              | 6                |                  |
| Ostatní  |            |      |      |        | 5                | 0                |               |                                       |                  |     |      |                  | 5                |                  |
|  |            |      |      |        |                  |                  |               | 2x 4/162, 3x 4/179                    |                  |     |      |                  |                  |                  |
| <b>(390) Renin</b>   | [ng/L]     |      |      |        | 6                |                  |               |                                       |                  |     |      | 5                | 5                | 100%             |
| Vzorky a skupiny   |            |      |      |        |                  |                  |               |                                       |                  |     |      |                  |                  |                  |
| <b>Vzorek A</b>  |            | 46,3 | 3,0  | 6,6    | 6                |                  |               |                                       |                  |     |      | 5                | 5                | 100%             |
| Ostatní  |            |      |      |        | 6                | 0                |               |                                       |                  |     |      |                  | 5                |                  |
|  |            |      |      |        |                  |                  |               | 1x 1/36, 4x 4/164, 1x 4/183           |                  |     |      |                  |                  |                  |
| <b>Vzorek B</b>  |            | 61,3 | 7,5  | 12     | 6                |                  |               |                                       |                  |     |      | 5                | 5                | 100%             |
| Ostatní  |            |      |      |        | 6                | 0                |               |                                       |                  |     |      |                  | 5                |                  |
|  |            |      |      |        |                  |                  |               | 1x 1/36, 4x 4/164, 1x 4/183           |                  |     |      |                  |                  |                  |
| <b>(394) SHBG</b>  | [nmol/L]   |      |      |        | 15               |                  |               |                                       |                  |     |      | 15               | 15               | 100%             |
| Vzorky a skupiny   |            |      |      |        |                  |                  |               |                                       |                  |     |      |                  |                  |                  |
| <b>Vzorek A</b>  |            | 34,1 | 1,9  | 5,6    | 15               |                  |               |                                       |                  |     |      | 15               | 15               | 100%             |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(60) Roche           |            | 34,9 | 0,52 | 1,5    | 5                | 0                | CVPG          | 32,3                                  | 0,26             | 20% | 25,8 | 38,8             | 5                |                  |
| Ostatní  |            |      |      |        | 10               | 0                |               |                                       |                  |     |      |                  | 10               |                  |
|  |            |      |      |        |                  |                  |               | 4x 4/1, 4x 4/12, 2x 4/29              |                  |     |      |                  |                  |                  |
| <b>Vzorek B</b>  |            | 61,7 | 5,0  | 8,0    | 15               |                  |               |                                       |                  |     |      | 15               | 15               | 100%             |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(60) Roche           |            | 65,0 | 1,4  | 2,2    | 5                | 0                | CVPG          | 61,3                                  | 0,50             | 20% | 49   | 73,6             | 5                |                  |
| Ostatní  |            |      |      |        | 10               | 0                |               |                                       |                  |     |      |                  | 10               |                  |
|  |            |      |      |        |                  |                  |               | 4x 4/1, 4x 4/12, 2x 4/29              |                  |     |      |                  |                  |                  |
| <b>(327) Vitamin B12</b>                                   | [pmol/L]   |      |      |        | 28               |                  |               |                                       |                  |     |      | 28               | 28               | 100%             |
| Vzorky a skupiny   |            |      |      |        |                  |                  |               |                                       |                  |     |      |                  |                  |                  |
| <b>Vzorek A</b>  |            | 261  | 36   | 14     | 28               |                  |               |                                       |                  |     |      | 28               | 28               | 100%             |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(1) Abbott           |            | 263  | 21   | 8,1    | 10               | 0                | CVPG          | 256                                   | 5,6              | 20% | 204  | 308              | 10               |                  |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(12) Beckman Coulter |            | 193  | 11   | 5,8    | 5                | 0                | CVPG          | 186                                   | 4,9              | 20% | 148  | 224              | 5                |                  |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(60) Roche           |            | 290  | 10   | 3,6    | 7                | 0                | CVPG          | 287                                   | 2,5              | 20% | 229  | 345              | 7                |                  |
| Ostatní  |            |      |      |        | 6                | 0                |               |                                       |                  |     |      |                  | 6                |                  |
|  |            |      |      |        |                  |                  |               | 2x 4/29, 1x 4/149, 2x 4/162, 1x 4/179 |                  |     |      |                  |                  |                  |
| <b>Vzorek B</b>  |            | 903  | 120  | 14     | 28               |                  |               |                                       |                  |     |      | 28               | 28               | 100%             |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(1) Abbott           |            | 960  | 110  | 12     | 10               | 0                | CVPG          | 930                                   | 18               | 20% | 744  | 1120             | 10               |                  |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(12) Beckman Coulter |            | 756  | 89   | 12     | 5                | 0                | CVPG          | 754                                   | 19               | 20% | 603  | 905              | 5                |                  |
| (4) LIA (CLIA, CMIA, ECLIA, LOCI);<br>(60) Roche           |            | 916  | 40   | 4,4    | 7                | 0                | CVPG          | 919                                   | 5,2              | 20% | 735  | 1110             | 7                |                  |
| Ostatní  |            |      |      |        | 6                | 0                |               |                                       |                  |     |      |                  | 6                |                  |
|  |            |      |      |        |                  |                  |               | 2x 4/29, 1x 4/149, 2x 4/162, 1x 4/179 |                  |     |      |                  |                  |                  |
| <b>(319) Vitamin B12 (aktivní)</b>                         | [pmol/L]   |      |      |        | 7                |                  |               |                                       |                  |     |      | 6                | 6                | 100%             |
| Vzorky a skupiny   |            |      |      |        |                  |                  |               |                                       |                  |     |      |                  |                  |                  |
| <b>Vzorek A</b>  |            | 76,1 | 11   | 14     | 7                |                  |               |                                       |                  |     |      | 6                | 6                | 100%             |
| Ostatní  |            |      |      |        | 7                | 0                |               |                                       |                  |     |      |                  | 6                |                  |
|  |            |      |      |        |                  |                  |               | 3x 4/1, 3x 4/60, 1x 4/179             |                  |     |      |                  |                  |                  |
| <b>Vzorek B</b>  |            | 274  | 27   | 10     | 7                |                  |               |                                       |                  |     |      | 0                | 0                |                  |
| Ostatní  |            |      |      |        | 7                | 0                |               |                                       |                  |     |      |                  | 0                |                  |
|  |            |      |      |        |                  |                  |               | 3x 4/1, 3x 4/60, 1x 4/179             |                  |     |      |                  |                  |                  |

st\_kn\_p

Konec sestavy

Vytištěno: 30.07.2022